Large-Scale Proteomic Analysis of Patients with Type 2 Diabetes Mellitus and Atherosclerosis Using a Label-Free LC-MS/MS Approach

dc.authorid0000-0002-4502-9670
dc.contributor.authorSurmen, Mustafa Gani
dc.contributor.authorBozkaya, Tijen Alkan
dc.contributor.authorAtes, M. Sanser
dc.contributor.authorSurmen, Saime
dc.contributor.authorCakici, Cagri
dc.contributor.authorPençe, Sadrettin
dc.contributor.authorEmekli, Nesrin
dc.date.accessioned2025-05-10T19:58:09Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective: Type Type 2 diabetes mellitus (T2D) is a metabolic disease whose molecular events have not yet been fully clarified. However, next- generation powerful molecular approaches such as mass spectrometry (MS)-based proteomics holds promise. In this study, we aimed to reveal the protein profile of serum samples obtained from patients with T2D and atherosclerotic cardiovascular disease using the high- resolution liquid chromatography (LC)-MS/MS system. Materials and Methods: Immune depletion was performed for the top 12 abundant proteins in 10 mu l serum samples taken from individuals. Then, tryptic peptides were obtained from total proteins by applying a digestion protocol. Accordingly, reduction, alkylation, and digestion with trypsin enzyme were carried out, respectively. Tryptic peptides were analyzed in an ultra-high-pressure LC-MS/MS system with a label-free proteomic approach. The raw data were processed using the software program. Results: LC-MS/MS analyses revealed 120 proteins with significant expression changes. Some of these proteins were associated with inflammation, lipid transport, and oxidative stress, which are known to play an important role in T2D and its complications. Conclusion: As a result, LC-MS/MS analyses highlighted the proteins that will provide predictions in the treatment and course of T2D. We believe that validation of these proteins with targeted proteomic approaches in a larger sample in further studies will contribute to the development of clinically usable panels.
dc.description.sponsorshipIstanbul Medipol University Scientific Research Projects [2019/16]
dc.description.sponsorshipFinancial Disclosure: This study was supported by Istanbul Medipol University Scientific Research Projects (Project Number: 2019/16) .
dc.identifier.doi10.26650/experimed.1219362
dc.identifier.endpage38
dc.identifier.issn2667-5846
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85173962083
dc.identifier.scopusqualityQ4
dc.identifier.startpage26
dc.identifier.trdizinid1177371
dc.identifier.urihttps://doi.org/10.26650/experimed.1219362
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1177371
dc.identifier.urihttps://hdl.handle.net/20.500.14730/13448
dc.identifier.volume13
dc.identifier.wosWOS:001322143900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Univ
dc.relation.ispartofExperimed
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectDiabetes
dc.subjectproteomics
dc.subjectserum
dc.subjectmass spectrometry
dc.subjectatherosclerosis
dc.titleLarge-Scale Proteomic Analysis of Patients with Type 2 Diabetes Mellitus and Atherosclerosis Using a Label-Free LC-MS/MS Approach
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
13448.pdf
Boyut:
1.29 MB
Biçim:
Adobe Portable Document Format